Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (39)	5/2/2001 7:35:19 PM
From: keokalani'nui	Respond to of 1840

Maybe this is nothing. Beats me. Got USF involved for the trials. Wednesday May 2, 5:50 pm Eastern Time Press Release SOURCE: SLIL Biomedical Corp. IND Filed on New Aids-Cancer Drug From SLIL MADISON, Wis., May 2 /PRNewswire/ -- SLIL Biomedical Corp. announced that the IND (Investigational New Drug application) for its first candidate drug, SL11047, was filed today. ``This is the culmination of several years' work and an important milestone for the company,'' commented SLIL President and CEO, Peter Molloy. The drug, SL11047, is one of SLIL's newer generations of polyamine analogs. These are compounds that are thought to act by attaching to DNA and preventing cells from dividing. Polyamine analogs have been studied extensively as potential anti-cancer agents, but the first generation drugs were limited by toxicity concerns. ``SLIL is the only company to progress beyond the first generation polyamine analogs,'' Molloy said. SL11047 is a second generation compound. ``We now have other second and third generation lead compounds and, last year, filed a patent on fourth generation polyamine compounds. SLIL is the world leader in the polyamine field.'' In addition to SL11047, SLIL has a pipeline of more than a dozen lead compounds, with its second candidate drug, SL11093, already in preclinical development for prostate cancer. The SL11047 trial is targeted to commence in June at the University of California San Francisco, principally sited at San Francisco General Hospital. Initially, it will be aimed at AIDS-related lymphoma (ARL) -- an incurable and usually fatal cancer associated with AIDS. Given the nature and severity of the disease, the trial will be conducted as a phase I/II trial. ``During the phase I stage, we will be assessing the tolerability of the drug on ARL patients by gradually escalating the dose of SL11047. As soon as a clinical response is seen, the phase II stage commences,'' Molloy said. If the drug proves to be tolerated and as effective as the company expects, SLIL will seek ``fast-track'' FDA review, which could see the drug on the market as early as 2004. The company also expects to see the trial expanded to non-AIDS lymphoma before the end of 2001, but this indication should have a longer timeline to market.